Infertility
Conditions
Keywords
Infertility, Tachykinin, Kisspeptin
Brief summary
The purpose of this project is to study the presence of expression differences - at RNA and protein level - of different members of the tachykinin family and kisspeptin and their receptors, between fertile women and infertile patients with different etiologies.
Interventions
PROCEDUREOvarian puncture
Donors and patients are subjected to ovarian puncture as part of their donation procedure or IVF treatment. Oocyte are retrieved in this procedure along with granulosa and cumulus cells. Donors and patients sign an informed consent in order to donate their granulosa and cumulus cells for the study.
Sponsors
Vida Recoletas Sevilla
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
Two groups of subjects (each one with different criteria): 1. Oocyte donors Inclusion Criteria: * Age between 18 and 34 years * Normal caryotype * Normal psychological test
Exclusion criteria
* Presence of hereditary diseases * Beta-thalassemia * Cystic fibrosis * Human immunodeficiency virus (HIV), Hepatitis B virus (HBV), Hepatitis C virus (HCV) 2. Infertility patients Inclusion Criteria: * Age between 18 and 45 years * One of the following etiologies: * Patient with PCOS according to Rotterdam Criteria or * Patients with endometriosis stage I-IV or * Patients with low ovarian response according to Bologna criteria or * Patients with advances maternal age (between 38 and 45 years)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Expression level of Substance P (SP) | 4 years | Expression analysis at mRNA (mRNA = messenger ribonucleic acid) and protein level using techniques of real time quantitative PCR (PCR = polymerase chain reaction), immunocytochemistry and western blot |
| Expression level of neurokinin A (NKA) | 4 years | Expression analysis at mRNA and protein level using techniques of real time quantitative PCR, immunocytochemistry and western blot |
| Expression level of neurokinin B (NKB) | 4 years | Expression analysis at mRNA and protein level using techniques of real time quantitative PCR, immunocytochemistry and western blot |
| Expression level of hemokinin 1 (HK-1) | 4 years | Expression analysis at mRNA and protein level using techniques of real time quantitative PCR, immunocytochemistry and western blot |
| Expression level of neurokinin 1 receptor (NK1R) | 4 years | Expression analysis at mRNA and protein level using techniques of real time quantitative PCR, immunocytochemistry and western blot |
| Expression of neurokinin 2 receptor (NK2R) | 4 years | Expression analysis at mRNA and protein level using techniques of real time quantitative PCR, immunocytochemistry and western blot |
| Expression level of neurokinin 3 receptor (NK3R) | 4 years | Expression analysis at mRNA and protein level using techniques of real time quantitative PCR, immunocytochemistry and western blot |
| Expression level of kisspeptin 1 (KISS1) | 4 years | Expression analysis at mRNA and protein level using techniques of real time quantitative PCR, immunocytochemistry and western blot |
| Expression level of kisspeptin 1 receptor (KISS1R) | 4 years | Expression analysis at mRNA and protein level using techniques of real time quantitative PCR, immunocytochemistry and western blot |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Years of infertility | 4 years | Number of years that the patient has been trying to have a child without success |
| Daily and total dose of FSH (FSH = follicle stimulating hormone) | 4 years | Daily dose of FSH for controlled ovarian stimulation. International Units (IU) |
| Progesterone level (day of ovulation induction) | 4 years | Progesterone level in blood (ng/mL), measured the day in which ovulation is induced |
| Estradiol level (day of ovulation induction) | 4 years | Estradiol level in blood (pg/mL), measured the day in which ovulation is induced |
| Daily and total dose of HMG (HMG = human menopausal gonadotropin) | 4 years | Daily dose of HMG for controlled ovarian stimulation. International Units (IU) |
| Type of ovulation induction | 4 years | Ovulation induction using 6500 IU of hCG (hCG = human chorionic gonadotropin) or 0.2 mg of triptorelin (Decapeptyl) |
| Number of oocytes retrieved in the ovarian puncture | 4 years | — |
| Number of mature oocytes (metaphase II) obtained in the ovarian puncture | 4 years | — |
| Fertilization rate | 4 years | Proportion of oocytes correctly fertilized (2 pronuclei and 2 polar bodies) after the ICSI (ICSI = intracytoplasmic sperm injection) procedure |
| Embryo quality | 4 years | Embryo quality at day 3 of embryo development (of each embryo of the cohort). Quality assessed according to ASEBIR (ASEBIR = Asociación Española para el estudio de la Biología de la Reproducción = Spanish society for reproductive biology) criteria. Embryo quality grade A to D. |
| Patient or donor age | 4 years | Years |
| Patient or donor body mass index | 4 years | kg/m2 |
Countries
Spain
Outcome results
None listed